



Meet your **October 6th, 2021 IWMF** **Virtual Ed Forum Speakers**



WM & Basic Terminology

Jeffery Mateous, MD

Medical Director, Colorado Blood Cancer Institute

Jeffrey V. Mateous MD is presently the Medical Director at the Colorado Blood Cancer Institute, and Clinical Professor of Medicine at the University of Colorado. After graduating from Medical School in 1985 from the University of Washington, he completed an Internal Medicine residency and chief residency at the University of Colorado. Fellowship training in Hematology and BMT followed at the University of Washington and the Fred Hutchinson Cancer Research Center, where he worked in the lab of Dr. Ken Kaushansky. Since 1994 he has worked in private practice in Denver focusing exclusively on the care of patients with blood cancers, focusing on WM, myeloma and amyloidosis. He is an enthusiastic educator and a member of committees of both ASH & ASCO. Most prominently he has been married for many years to Marie, and three children: Ben, Joe & Catherine. He enjoys cycling, languages and is a passionate fan of our nation's pastime.



Meet your **October 6th, 2021** IWMF Virtual Ed Forum Speakers



Understanding Your Blood & Bone Marrow Tests

Rafat Abonour, MD

Harry and Edith Gladstein Professor of Cancer Research

Professor of Medicine, Pathology and Laboratory Medicine

Director, Multiple Myeloma, Waldenstrom's Disease and Amyloidosis Program

Rafat Abonour, MD is Professor of medicine, pathology, and laboratory medicine at Indiana University where has worked since 1995. Dr Abonour earned his medical degree from the University of Damascus in Syria. He completed his residency in internal medicine and fellowship in hematology at the University of Wisconsin in Madison, Wisconsin.

Dr Abonour established the multiple myeloma and plasma cell program at Indiana University. His clinical interests include studying novel therapies including immunotherapy, quality of life, and precursor conditions. Dr Abonour is principal or co-investigator of several completed and on-going clinical trials. Dr Abonour has authored or coauthored numerous peer-reviewed manuscripts, book chapters, and review articles. His works published in key medical research journals including Blood, New England Journal of Medicine and Nature Medicine.

Dr Abonour is a member of the Eastern Cooperative Group Data Monitoring Committee for Myeloma, the Scientific Research Committee at Indiana Cancer Center, and the Indiana University Executive Review Board. Dr Abonour has joined the International Myeloma Foundation in 2015 as their medical liaison to Europe. In addition, he is actively involved in a number of professional societies including the American Society of Hematology and the American Society of Clinical Oncology. He has lectured nationally and internationally and received numerous awards, including the Trustee Teaching Award from Indiana University and the Excellence in Cancer Care Award from the Indianapolis Leukemia and Lymphoma Society. Dr Abonour, M.D., received a Sagamore of the Wabash, the highest honor an Indiana governor can bestow in 2010.



Meet your **October 6th, 2021** IWMF Virtual Ed Forum Speakers



Genomics/Science of WM

Sikander Ailawadhi, MD

Professor with the Division of Hematology-Oncology at Mayo Clinic, Jacksonville

Dr. Ailawadhi is a Professor with the Division of Hematology-Oncology at Mayo Clinic in Jacksonville and joined the Division in 2014 when he moved from the University of Southern California, Los Angeles where he was an academic faculty with Hematology. His career focus has been on treatment of plasma cell disorders, namely multiple myeloma and Waldenström's macroglobulinemia, and also chronic lymphocytic leukemia. His research has focused on understanding the epidemiology and pathophysiology of these disorders, evaluating the benefit of various therapeutic strategies in different populations based on racial-ethnic and socioeconomic diversity, as well as developing novel therapeutics by means of conducting several regional and national clinical trials. These have included phase 1 through phase 3 clinical trials for novel drugs including cellular therapy such as car T-cell treatment. Dr. Ailawadhi has a special interest in understanding the disparities in care of cancer patients and their outcomes with a special focus on patients from different racial and ethnic backgrounds. To achieve this he has done several extensive analyses from large national databases and is focused on improving clinical trial accrual across the country, especially for patients from racial and ethnic minorities.
